CVS Health Stock Receives Strong Buy Rating from Analysts
CVS Health Corporation (NYSE: CVS) has seen strong performance in recent years, with its stock surging by nearly 34.9% in 2026 and outperforming the S&P 500 Index ($SPX). The company's Q1 2026 earnings exceeded expectations, reporting revenue of $100.4 billion and adjusted EPS of $2.57. Analysts remain optimistic about its prospects for the year ahead. Among the 24 analysts covering CVS stock as of July 28, 2026, there is a consensus rating of 'Strong Buy,' with 20 such ratings, two 'Moderate Buys,' and two 'Holds.' Goldman Sachs analyst Scott Fidel recently reaffirmed his 'Buy' stance on the stock with a price target of $116. The mean price target among analysts stands at $112.29, representing a potential 4.9% upside from current levels. CVS is expected to report full-year EPS in the range of $7.30–$7.50 per share and revenue of approximately $405 billion for fiscal year ending December 2026.
Topics: analyst sentiment CVS Health earnings report stock performance